Ha Tay Pharmaceutical JSC

  • Market Cap: Small Cap
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: VN000000DHT3
VND
72,800.00
-200 (-0.27%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-summaryCompany CV
About Ha Tay Pharmaceutical JSC stock-summary
stock-summary
Ha Tay Pharmaceutical JSC
Pharmaceuticals & Biotechnology
Hatay Pharmaceutical Joint Stock Company (Hataphar) is a Vietnam-based pharmaceutical company. It is engaged in the manufacturing, marketing, wholesale and retail trading, import and export of pharmaceutical products, preparations and materials, vaccines, along with medical equipment and supplies. The Company also manufactures and trades cosmetic products, supplemental food, general chemicals and specialized chemicals for laboratory tests. Other activities include supermarket operations, office and apartment leasing, real estate brokerage services, as well as the provision of vocational training services. The Company announced that it has completed the acquisition of 50.626% stake in Ha Tay Pharmaceutical and Medical Equipments Joint Stock Company by the end of the third quarter of 2013.
Company Coordinates stock-summary
Company Details
10A Quang Trung, Ha Dong , HANOI None : None
Registrar Details
stock-recommendation Shareholding
Shareholding Snapshotstock-summary
Icon
No data for shareholding present.
Shareholding Compare (%holding) stock-summary
Icon
No data for shareholding present.
stock-summary Board of Directorsstock-summary
Management
Designation
Mr. Lo Le
Chairman of the Board of Management
Mr. Trung Le
Vice Chairman of the Board of Management, Deputy General Director
Tue Hoang
Chief Accounting Officer, Member of the Board of Management
Mr. Thang Le
General Director, Member of the Board of Management
Ms. Linh Le
Deputy General Director, Member of the Board of Management
Lai Nguyen
Deputy General Director of Production, Member of the Board of Management
Mr. Thang Nguyen
Director of Investment Projects, Member of the Board of Management
stock-recommendation Stock DNA
Revenue and Profits:
Net Sales:
574,351 Million
(Quarterly Results - Jun 2025)
Net Profit:
13,409 Million
stock-summary
Industry

Pharmaceuticals & Biotechnology

stock-summary
Market cap

VND 6,611,905 Million (Small Cap)

stock-summary
P/E

90.00

stock-summary
Industry P/E

NA

stock-summary
Dividend Yield

0.00%

stock-summary
Debt Equity

0.28

stock-summary
Return on Equity

6.43%

stock-summary
Price to Book

6.14